Chimeric proteins for cancer immunotherapy can combine different activities by
displaying both agonistic and antagonistic properties on a single molecule. However, those usually exhibit toxicities related to their potency being exerted in the entire organism and notonly in tissues relevant for cancer treatment. This may be solved by using appropriatevectorization of the chimeric proteins to the tumour microenvironment, where immune cells interact with tumour cells expressing immunomodulatory molecules.
The present invention relates to a nucleic acid encoding a chimeric protein or a chimeric
protein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a signaling and/or targeting domain, (b) is a linker (b) is a functional linker and (c) is a signaling and/or targeting domain or N terminus - (c) - (b) - (a) - C terminus, wherein: (c) is a signaling and/or targeting domain, (b) is a linker (b) is a functional linker and (a) is a signaling and/or targeting domain.